Alaunos Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Hello, everyone. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company. It is my pleasure to have with me today, Kevin Boyle and Drew Deniger from Alaunos Therapeutics management. As a reminder, any viewers who are watching through our conference portal are able to submit questions via the Ask a Question box below the video feed window.
And with that, Kevin, you have the floor.
Good morning and thank you, Gil, to you and to Needham for the invitation to present at the conference today. And to the investors, we appreciate your interest in Alaunos Therapeutics and our TCR-T platform attacking solid tumors. I'm Kevin Boyle, the Chief Executive Officer of Alaunos, and today I will be joined by Drew, our Vice President of Research and Development.
Alaunos is laser-focused on leading the scientific development of T-cell receptor therapies to revolutionize how solid cancer treatment are performed and improve patient outcomes. In the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
